title: [Drug therapy for primary osteoporosis in men].
abstract: Overall, drug therapies for osteoporosis in men are less defined than in women, mainly due to the fact that there are fewer RCTs performed in male populations, to the relatively smaller sample sizes, and to the lack of long-term extension studies. In a series of well-designed RCTs, alendronate, risedronate, zoledronic acid, and teriparatide were demonstrated to reduce the risk of new vertebral fractures in men presenting with primary osteoporosis(including osteoporosis associated with low testosterone levels)and to improve the bone mineral density(BMD). In preliminary studies, ibandronate and denosumab also showed their beneficial effects on surrogate outcomes(BMD and markers of bone turnover)in men with osteoporosis. Although direct evidence about their non-vertebral anti-fracture efficacy are lacking, the effects of bisphosphonates, denosumab and teriparatide on surrogate outcomes were similar to those reported in pivotal RCTs undertaken in postmenopausal women, in which vertebral and non-vertebral anti-fracture efficacy have been clearly demonstrated.
authors.affiliation: Department of Orthopaedic Surgery and Rheumatology, Kindai University Nara Hospital, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Soen
mesh_terms: D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D004338:Drug Combinations; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy*; D058866:Osteoporotic Fractures / Q000453:epidemiology; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents; D004338:Drug Combinations